Cloud Hosting

NEW YORK--(BUSINESS WIRE)--Equity Data Science (EDS), a cloud-based analytics platform provider that delivers decision support tools for the investment process to hedge funds and asset managers, has named Theresa Elamparo as Head of Marketing to accelerate the companys business strategy and growth plan. Elamparo will lead all brand, marketing and communications strategies to continue to build the brand and to focus on the expansion of the business. She will be based in New York.

Elamparo brings 23 years of marketing communications experience, serving the fintech community for 16 years, most recently as Chief Marketing Officer at Tier1 Financial Solutions where she was the recipient of the 2019 Markets Media Women in Finance award for Excellence in Marketing and Communications for her work leading Tier1s rebrand and building the firms marketing organization. Prior to that, she held marketing leadership roles at fintech firms including Ipreo, Investment Technology Group and Tradeweb Markets.

We are thrilled to have Theresa join our leadership team, said Greg McCall, President and Co-founder at EDS. Her wealth of experience within the financial services industry and strategic marketing expertise will be integral to expanding our global footprint as we deliver on growing demand for data aggregation, analytics, workflow and scalable decision support for the fundamental investment process.

Im delighted to join EDS at such an exciting time, Elamparo said. The fundamental investment community is faced with fragmentation, underutilized data and technical inefficiencies. EDS provides a modular, decision-support workflow platform for the full investment lifecycle, helping clients better manage their process to maximize returns.

Throughout 2021, EDS invested heavily in building out solid leadership across key functions, including the appointment of Jen Vermeulen, CFA as Head of Sales, and Erin Greenfield as Head of Customer Success. These recent appointments strengthen EDSs ability to expand its position in fundamental investing. At the start of the year, Northern Trust announced a strategic investment in EDS, allowing for integration of EDSs decision-support tools with Northern Trusts core technology platforms to provide highly specialized and innovative solutions to the most sophisticated institutional investors across the globe.

ABOUT EQUITY DATA SCIENCEEquity Data Science (EDS) empowers fundamental investors to build, operate and sustain a modernized, repeatable investment process by aggregating data sources and refining workflows to govern investment decisions. EDS provides a fully configurable, measurable, and scalable platform with purpose-built analytics to support idea generation, research management, portfolio construction and risk management. Visit us at http://www.equitydatascience.com.

Here is the original post:

Equity Data Science Appoints Theresa Elamparo as Head of Marketing - Business Wire

Blockchain is the next big thing for data science

Innovative technologies such as big data and blockchain are being hailed as the next big things that will change the way businesses operate. Majority of us believe that these technologies are totally exclusive, with each having its own route of being employed independently. While data science focuses on using data for efficient administration, blockchains distributed ledger protects the data protection. These technologies offer a lot of untapped promise in terms of improving efficiency and productivity.

There hasnt been much work into the connection between blockchain and data science, if there is one. To put it another way, data is at the heart of each of these technologies. Data science focuses on generating relevant insights from the data for problem-solving, whereas blockchain certifies and stores data. Algorithms are used in each of these technologies to regulate interactions with various data segments. In a nutshell, data science is used to predict and blockchain is used to validate data.

Peer-to-peer partnerships are made easier using blockchain. If a published account, for example, fails to adequately explain any approach, any peer can analyse the entire process and determine how the results were reached.

Anyone can learn whether data is accurate to use, how to preserve it, how to update it, where it originates from and how to utilise it properly thanks to the ledgers open channels. To conclude, blockchain technology will allow users to track data from start to finish.

Real-time data analysis is extremely tough. The most effective approach of detecting fraudsters is to be capable of monitoring developments in real time. For a long period of time, though, real-time analysis wasnt really possible. Companies can now detect any irregularities in the dataset from the outset, thanks to blockchains decentralized nature.

Spreadsheets have a feature that allows you to see modifications in data in real time. Similarly, blockchain allows two or more individuals to collaborate on the same data and information.

The data in blockchains digital log is kept in a variety of nodes, both private and public. The data is cross-checked and examined at the entrance point before being added to further blocks. This procedure in and of itself is a means of data verification.

When data flows smoothly and easily, there are numerous benefits for organisations. With paper records, its quite tough. This problem is exacerbated when the information contained within it is needed elsewhere. True, these data will get the other division, but it may take a long time and there is a possibility that they will be lost in the process.

Several data scientists are interested in blockchain today because it allows two or more individuals to view data simultaneously and in real time.

As a result, when data moves freely, the administrative process becomes more efficient.

Biases are common when there is a central body, as you are well aware. Putting too much faith in one person might be dangerous. Because of trust difficulties, many businesses refuse to provide other parties access to their data. Sharing information becomes virtually impossible as a result of this. The trust issue does not stand in the way of exchange of information with the block chain. By sharing the knowledge, they have at their availability, businesses can interact efficiently.

The primary focus of corporations in the past decade was on increasing data storage capacity. That was fixed by the end of 2018. The new issue for most businesses is securing and validating the datas authenticity.

The fundamental reason for this is that organisations collect data from various sources. Even data gathered from government institutions or generated domestically can be prone to inaccuracies. Furthermore, data from other sources, such as social networks, may be erroneous.

Data scientists are now employing blockchain technology to assure data validity and trace it across the chain. Its unchangeable security is among the reasons for its widespread acceptance. Data is safeguarded at every step by multiple signatures on blockchains decentralised record. The precise signatures must be provided in order for anyone to obtain access to the data. As a result, occurrences of data hacking and breaches are greatly reduced.

The following are some of blockchains security aspects that are beneficial to data science:

Every transaction that occurs in Blockchains record is encrypted using complicated mathematical techniques. These transactions are recorded as digital contracts that are both immutable and irrevocable.

Data scientists frequently keep track of their companys information in data lakes. When using blockchain to monitor the provenance of data, it is recorded in a distinct block with a unique cryptographic key. This ensures that everybody who uses the data has the correct key from the person who created it, indicating that the data is correct, of excellent quality and authentic.

Share This ArticleDo the sharing thingy

Here is the original post:

Why is Blockchain the Next Big Thing for Data Science? - Analytics Insight

With a labor shortage straining the tech industry, companies are desperate for qualified engineers.

But Big Tech hasn't let up on its infamously intensive interview process. And a few skills are especially in demand as companies screen job candidates.

By brushing up on the skills companies test for, candidates can get the leg up they need to stand out in the tech hiring process. HackerRank, a website that companies like Amazon, Facebook, and Stripe use to search for would-be recruits and conduct interviews, told Insider the top five software skills that tech companies are testing for right now.

The most in-demand skills include popular programming languages but also other software-oriented competencies, like a financial-services software program. HackerRank compiled the data from year-to-date tests, measured through its customer base of 2,600 companies and 16 million developers.

Overall, the list signals that companies are interested in data-management skills, especially within the past year. Companies are increasingly screening for the skills and software needed to manage data visualization, modeling, and cleaning complex data, according to Vivek Ravisankar, CEO of HackerRank.

"Especially as more companies are trying to become more tech forward, data science and machine learning have come up quite a bit," Ravisankar told Insider.

Follow this link:

Top Technical Skills That Get People Hired, According to HackerRank - Business Insider

Vinehealth, a 2018-founded, London-based digital health startup thats built an app offering personalized support for cancer patients while also making it easier to gather patient-reported outcome (PRO) data, including for drug development and clinical trials, has closed a $5.5 million seed round as it prepares to expand into the U.S.

The round, which co-founder and CTO Georgina Kirby describes as a late seed ahead of a planned Series A in the next 12-18 months is led by Talis Capital with participation from previous investorsPlayfair CapitalandAscension.

A number of angel investors have also joined the round, including Keith Gibbs, former CEO of AXA PPP Healthcare; Pam Garside, partner at Newhealth; Voyagers Health-Tech Fund, led by David Rowan, founding editor of Wired; David Giampaolo, healthcare entrepreneur and founder of PI Capital; Deepali Nangia, venture partner at Speedinvest and Atomico Angel; Faisal Mehmud, VP and former medical director of Bristol Myers Squibb; and KHP MedTech Innovations, a collaboration between Kings College London, Kings College Hospital NHS Foundation Trust and Guys and St Thomas NHS Trust.

The startup which we billed as one to watch back in 2019 when we saw the founders pitching at Entrepreneur Firsts demo day combines behavioral science and AI to deliver timely patient support and nudges (for things like medication reminders) so they can more easily self-manage their treatment.

Vinehealths platform also acts as a channel through which patients can be remotely monitored by their clinicians as they provide feedback on symptoms and report any treatment side-effects.

So far its app has been downloaded around 15,000 times since being made available in January 2020 which Kirby confirms covers all usage to date, so both for pure patient-support and for trials/research.

The patient-support app is offered free for cancer patients to download themselves currently available in the U.K. and Ireland.

For pharma, Vinehealth provides its platform as a software as a service supporting drug companies in recruiting patients for trials and gathering PRO to help with R&D and drug development.

Weve been focused on pharma since the very beginning and were getting a lot of traction there and seeing a lot of opportunity, said Kirby. The patient support program and the clinical trial are extremely similar [products]. For pharma theyre different parts of the drug development process but in terms of the delivery of software, the things that patients need throughout that process its extremely similar. So weve really narrowed down to that life science offering.

She confirms Vinehealth is not going down the procurement route of trying to sell to healthcare services directly. So essentially the idea is for life sciences research to fund a free provision of the support software to patients. (Although it cant disclose any pharma customer names as yet.)

For monetization, its focused on serving the needs of drug companies, Vinehealth is equally keen to be seen as patient-centric and wants its app to play a key clinician support role that promotes better patient outcomes.

We have a web dashboard that is accessible through any browser for clinicians and doctors who want to be able to track their patients remotely and do this through running research studies or even within clinical trials, said Kirby. Those doctors and nurses can see that data in real-time but they can feed that into either appropriate points of the care pathway obviously theyre not sitting there on the dashboard all day, but there may times at which its very useful for them to see specific red flags and be able to know which patient to see first and also to know how to make better clinical decisions using that kind of more real-time data rather than the typical [fortnightly or monthly catch up with a patient].

So its kind of giving them that context and that rich longitudinal data that theyve never had, she added.

Vinehealth has digitized the traditional paper-based questionnaires that cancer patients would typically be asked to fill in during a visit with their clinical team to report their symptoms and provide any wider feedback.

Its premise is that moving that legacy process to a dedicated, user-friendly digital interface supports better patient self-management, treatment outcomes and improved quality of life for people living with cancer given the relative ease of reporting data via an app, combined with the wider support package it offers (its worked with charities Macmillan and Bowel Cancer UK to supply support content to the app).

For example, Kirby said they use A/B testing and AI to configure personalized and timely recommendations to surface appropriate resources, as well as to determine how best to nudge and motivate patients to take medications and manage what can be complex medication regimes for cancer treatment.

Vinehealths app wrapper can also dole out positive feedback to encourage patients to provide PRO.

Kirby points toevidence that when patients track their PRO data effectively, survival rates can increase by up to 20%. Better self-management can have such a huge impact on survival, she said. We want to show not only improvements in survival but in quality of life. too.

The blend of behavioral science and data-driven support Vinehealths approach involves stems from the combined expertise of the co-founders.

Raynas [Patel; co-founder and CEO] background is really in behavioral science; mine is in data science, said Kirby. And so when we came together, we thought we can really leverage both sides here and use the data to understand what people are going through and where those nudges can be most effective. And use behavioral science to deliver some really key nudges at the right time with the right wording that can really nudge people to build their habits and be able to feel more in control and be able to actually understand whats going on and make some better decisions for their own care.

There are a number of nudges in the app some small ones, some bigger ones. We build medication nudges and reminders to be delivered in a certain way that is really effective and isnt just dismissed by patients. We have nudges for logging certain symptoms and what that leads on to so certain supportive content. So youre logging anxiety at certain levels, heres some supportive content that could really help you with dealing with this particular symptom or side effect of your drug.

At different times its about the timing, the wording and the delivery of that nudge, she added. If you try to change too many things at once research shows that you dont change anything at all so weve really carefully thought about how we nudge and how we try to help patients build better habits and how often we do that as well.

Kirby says the goal in time is also to use AI to incorporate more advanced suggestions into the platform in the future, such as predictive symptom logging, i.e., what is likely to occur for this particular drug for this particular patient.

For now, Vinehealth has built a content recommender system that is specialized in oncology and personalized to the patient: tuned to their diagnosis, adapting to their ongoing input, and factoring in content that other similar patients are reading and finding supportive.

On the research side, Kirby says the largest study the platform has been used for to date is an ongoing study involving nine NHS Trusts and 300 patients which is a piece of research that Vinehealth is undertaking itself.

Health data is of course highly sensitive, and Kirby confirmed that consent for any third-party research purposes is sought separately to the consent a user of the patient-support product is asked for so that Vinehealth can process their medical information to provide the service and give them personalized treatment support.

That data is not shared with anybody unless they have [given] explicit consent to do that. By just signing up to the platform, theyre not consenting to sharing their data as part of a clinical trial. That is a completely separate piece of consent, she said.

We make it extremely clear and dont want to hide any sharing in any way it has to be really obvious and really clear to a patient. Ultimately everyone wants to support patients. They want to give more opportunities for patients to be in those clinical trials, to be able to capture that data and feed that back in a way where normally theyre suffering at home with these kind of side effects and thats never getting back to the pharma company, for example so were making it really clear what were doing and why were doing that and we give patients a choice.

Kirby suggested that, in the future, the startup may also look to be able to provide properly anonymized data sets based on purely aggregated insights provided by patients so it might, for example, be able to highlight demographic groups that experience particular side effects of certain drugs. However, she added that that is not something its doing at the moment given our focus on trials and patient support programs.

In the near term, Vinehealth is gearing up for growth via a U.S. launch which it hopes will happen early next year with the 18-strong team likely to double over the next six months or so and its first U.S. hire already locked in.

The main thing that weve been focused on since we fundraised is hiring a great team and growing that team and investing time in really building that out and making sure that everyones aligned on the mission and that were really building out a product thats scalable to be able to take into these new markets, Kirby said. Building a startup is all about having great people. You can have great technology but if you dont have great people, then you dont really have anything.

Commenting on the seed funding in a statement, Beatrice Aliprandi, principal at Talis Capital, said: Were hugely excited to be partnering with Rayna and Georgina: Wed been keeping a close eye on Vinehealths growth for several months before we invested in the company, given its unique value proposition where healthcare outcomes work in direct correlation with financial outcomes. Its a win-win-win for patients, hospitals and pharmaceutical companies, which is rarely the case in the healthcare space where parties are often at odds with one another.

From our first meeting, the resilience and mission-driven attitude of the founders was immediately clear and is really what made this opportunity so compelling. Both Rayna and Georgina are clearly incredibly driven to improve the lives and survival of cancer patients, and as a team they possess a unique combination of expertise, skills, and drive to make Vinehealth a success.

Original post:

Vinehealth, offering digital support for cancer patients and SaaS for R&D, gets $5.5M to launch in the US - TechCrunch

PARAMUS,N.J., Dec. 3, 2021 /PRNewswire/ --SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, will present new post-hoc, retrospective analyses of the long-term safety and efficacy of its anti-seizure medication (ASM) XCOPRI (cenobamate tablets) CV at the American Epilepsy Society (AES) Annual Meeting, held December 3-7, 2021 in Chicago, Illinois and virtually through AES 2021 Digital Select. The analyses examined data collected from a subset of 240 patients with partial-onset seizures who participated in the long-term, open-label multicenter phase 3 safety study (C021). As of the last clinic visit analyzed on or after September 1, 2019, 74% (n=177) of patients remained on XCOPRI with results showing early onset responder rates and high rates of sustained seizure reductions across a variety of seizure types for as long as 43 months (median 30.2 months).1,2

In an analysis of patients by focal seizure subtype including focal aware motor (FAM), focal impaired awareness (FIA), and focal to bilateral tonic-clonic (FBTC), seizure reductions of at least 50% occurred in 56% (15/27) of FAM patients, 51% (114/223) of FIA patients, and 70% of FBTC patients during the initial 12-week titration phase.1 Seizure reductions of 100% were observed during titration in 22% (6/27), 22% (48/223), and 50% (28/56) of the FAM, FIA, and FBTC seizure subtype groups, respectively. During months 24-27, complete seizure reduction occurred in 48% (11/23) of patients with FAM seizures, 54% (88/162) of patients with FIA seizures, and 91% (38/42) of patients with FBTC seizures.1 Additionally, in an analysis of patients (n=85) who had previously received epilepsy-related surgery and continued to experience frequent seizures (average 26 seizures per month), 31% (26/85) maintained seizure freedom for at least 12 consecutive months during exposure to cenobamate (median exposure ~2.5 years).2

"I am encouraged to see that patients across a variety of focal seizure subtypes are having a response to treatment with XCOPRI for an extended period of time," said William E. Rosenfeld, MD, epileptologist/neurologist principal investigator at the Comprehensive Epilepsy Care Center for Children and Adults in St. Louis, Missouri. "Based on these findings, XCOPRI may be an option for patients both early in their treatment regimen as well as later on, if prior treatments including surgery have been unsuccessful."

Safety data in this patient subset is consistent with the safety data in the larger cohort from the C021 study4, with the most commonly observed treatment-emergent adverse events being fatigue, dizziness, and somnolence.1,2

SK life science is presenting six posters at AES, which are available here. To see the SK life science virtual booth at AES, please visit StepIntoXcopri.com.

About Study C021Study C021 was a large, multi-center, open-label Phase 3 study assessing the safety of cenobamate as adjunctive therapy in 1,340 adults (18-70 years old) with uncontrolled focal seizures taking 1-3 anti-seizure medications (ASMs). The objectives of the study included the characterization of the long-term safety of cenobamate and to understand how to best add cenobamate to regimens that included phenytoin or phenobarbital. In addition, the study was designed to determine the rate of DRESS in at least 1,000 patients taking cenobamate for at least 6 months, using a low starting dose and every other week titration; no cases of DRESS occurred in the study. Cenobamate was initiated at 12.5 mg/day and increased at 2-week intervals to 25, 50, 100, 150 and 200 mg/day. Further increases to 400 mg/day using bi-weekly 50 mg/day increments were allowed.

AboutXCOPRI (cenobamatetablets) CVCenobamateis an anti-seizure medication (ASM)discovered and developed by SK Biopharmaceuticals and SK life science. While theprecise mechanism by whichcenobamateexerts its therapeutic effect is unknown, it is believed toreduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positiveallosteric modulator of the -aminobutyric acid (GABAA) ion channel.

Cenobamateis approved in the United States for the treatment ofpartial-onset seizures inadults andis available under the brand name XCOPRI (cenobamatetablets) CV.Cenobamatecan be combined with other ASMs or used alone.The recommended initial dosage ofcenobamateis 12.5 mg once-daily, with titration every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

Cenobamateis also approved in the European Union and the United Kingdomfor the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with seizuresthathave not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinalproductsand is marketed by Angelini Pharma under the brand nameONTOZRY.

Additionally,cenobamateis in clinical development in Asia. Ono Pharmaceutical and Ignis Therapeutics have the rights to develop and commercializecenobamatein Japan and in the Greater China region, respectively.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI(cenobamate tablets) CV

DO NOT TAKE XCOPRI IF YOU:

XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells.You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away.Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider.

QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening).Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.

Suicidal behavior and ideation:Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood.

Nervous system problems:XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems.Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you.

Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider.

DISCONTINUATION:

Do not stop taking XCOPRI without first talking to your healthcare provider.Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

DRUG INTERACTIONS:

XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works.Do not start or stop other medicines without talking to your healthcare provider.Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

PREGNANCY AND LACTATION:

XCOPRI may cause your birth control medicine to be less effective.Talk to your health care provider about the best birth control method to use.

Talk to your health care provider if you are pregnant or plan to become pregnant.It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go towww.aedpregnancyregistry.org.

Talk to your health care provider if you are breastfeeding or plan to breastfeed.It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI.

COMMON SIDE EFFECTS:

The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired.

These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088or atwww.fda.gov/medwatch.

DRUG ABUSE:

XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence.Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law.

INDICATION:

XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age.

Please see additional patient information in theMedication Guide. This information does not take the place of talking with your healthcare provider about your condition or your treatment.

Please see fullPrescribing Information.

About EpilepsyEpilepsy is the fourth most common neurological disorder. There are approximately 3.4 million people living with epilepsy in the United States, with 150,000 news cases each year in the country.4,5Epilepsy is characterized by recurrent, unprovoked seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but often the cause is completely unknown. Having seizures and epilepsy can affect one's safety, relationships, work, driving, and much more.6,7People with epilepsy are at risk for accidents and other health complications,including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).6,7Despite the availability of many antiepileptic therapies, almost 40percentof people with epilepsy are not able to achieve seizure freedom, meaning they have epilepsy that remains uncontrolled.8

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website atwww.skbp.com/engand SK life science's website atwww.SKLifeScienceInc.com.

Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments witha number ofcompetitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visithttp://hc.sk.co.kr/en/.

XCOPRI and ONTOZRY are registered trademarks of SK Biopharmaceuticals Co., Ltd.

References

SOURCE SK Life Science, Inc.

Link:

SK life science Presents Long-Term Data of XCOPRI (cenobamate tablets) CV in Adults with Partial-Onset Seizures at the American Epilepsy Society 2021...